Terms: = Small Cell Lung Cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Prognosis
600 results:
1. CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradation.
Quintanal-Villalonga A; Kawasaki K; Redin E; Uddin F; Rakhade S; Durani V; Sabet A; Shafer M; Karthaus WR; Zaidi S; Zhan YA; Manoj P; Sridhar H; Kinyua D; Zhong H; Mello BP; Ciampricotti M; Bhanot UK; Linkov I; Qiu J; Patel RA; Morrissey C; Mehta S; Barnes J; Haffner MC; Socci ND; Koche RP; de Stanchina E; Molina-Pinelo S; Salehi S; Yu HA; Chan JM; Rudin CM
Signal Transduct Target Ther; 2024 Jul; 9(1):189. PubMed ID: 39054323
[TBL] [Abstract] [Full Text] [Related]
2. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer.
Sen T; Takahashi N; Chakraborty S; Takebe N; Nassar AH; Karim NA; Puri S; Naqash AR
Nat Rev Clin Oncol; 2024 Aug; 21(8):610-627. PubMed ID: 38965396
[TBL] [Abstract] [Full Text] [Related]
3. The Evolving Scenario of ES-SCLC Management: From Biology to New cancer Therapeutics.
Trillo Aliaga P; Del Signore E; Fuorivia V; Spitaleri G; Asnaghi R; Attili I; Corvaja C; Carnevale Schianca A; Passaro A; de Marinis F
Genes (Basel); 2024 May; 15(6):. PubMed ID: 38927637
[TBL] [Abstract] [Full Text] [Related]
4. Evaluating the Clinical Characteristics and prognosis of Advanced Non-small cell lung cancer with Exon 20 Insertions.
Wang H; Xu Y; Lin J; Huang Y
Cancer Control; 2024; 31():10732748241262190. PubMed ID: 38857163
[TBL] [Abstract] [Full Text] [Related]
5. SWI/SNF family mutations in advanced NSCLC: genetic characteristics and immune checkpoint inhibitors' therapeutic implication.
Pang LL; Zhou HQ; Zhang YX; Zhuang WT; Pang F; Chen LJ; Liao J; Huang YH; Mao TQ; Mai ZH; Zhang L; Fang WF
ESMO Open; 2024 Jun; 9(6):103472. PubMed ID: 38833972
[TBL] [Abstract] [Full Text] [Related]
6. The clinicopathological features and possible physiological mechanisms of only the EGFR-T790M primary mutation in patients with lung adenocarcinoma.
Zhao P; Xu L; Zhu H; Ding W; Tang H
Pathol Res Pract; 2024 Jul; 259():155352. PubMed ID: 38781763
[TBL] [Abstract] [Full Text] [Related]
7. Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC.
Bao Z; Yu X; Zheng K; Zhai K; Cui H; Xu M
Front Immunol; 2024; 15():1372279. PubMed ID: 38756778
[TBL] [Abstract] [Full Text] [Related]
8. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract] [Full Text] [Related]
9. [Clinical characteristics and prognosis analysis of pulmonary sarcomatoid carcinoma].
Feng XY; Chen MJ; Xu Y; Zhong W; Liu XY; Gao XX; Zhao J; Wang MZ
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):319-324. PubMed ID: 38599806
[No Abstract] [Full Text] [Related]
10. Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer.
Bi YY; Chen Q; Yang MY; Xing L; Jiang HL
Nat Commun; 2024 Mar; 15(1):2759. PubMed ID: 38553451
[TBL] [Abstract] [Full Text] [Related]
11. The interplay between autophagy and apoptosis: its implication in lung cancer and therapeutics.
Biswas U; Roy R; Ghosh S; Chakrabarti G
Cancer Lett; 2024 Mar; 585():216662. PubMed ID: 38309614
[TBL] [Abstract] [Full Text] [Related]
12. UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
Liu S; Chai T; Garcia-Marques F; Yin Q; Hsu EC; Shen M; Shaw Toland AM; Bermudez A; Hartono AB; Massey CF; Lee CS; Zheng L; Baron M; Denning CJ; Aslan M; Nguyen HM; Nolley R; Zoubeidi A; Das M; Kunder CA; Howitt BE; Soh HT; Weissman IL; Liss MA; Chin AI; Brooks JD; Corey E; Pitteri SJ; Huang J; Stoyanova T
Cell Rep Med; 2024 Feb; 5(2):101381. PubMed ID: 38244540
[TBL] [Abstract] [Full Text] [Related]
13. Non-invasive decision support for clinical treatment of non-small cell lung cancer using a multiscale radiomics approach.
Zhang X; Zhang G; Qiu X; Yin J; Tan W; Yin X; Yang H; Wang H; Zhang Y
Radiother Oncol; 2024 Feb; 191():110082. PubMed ID: 38195018
[TBL] [Abstract] [Full Text] [Related]
14. Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer.
Provencio-Pulla M; Pérez-Parente D; Olson S; Hasan H; Balea BC; Rodríguez-Abreu D; Piqueras ML; Pal N; Wilkinson S; Vilas E; Ruiz-Gracia P; Cobo-Dols M
Clin Transl Oncol; 2024 Jun; 26(6):1384-1394. PubMed ID: 38183584
[TBL] [Abstract] [Full Text] [Related]
15. Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer.
Wang L; Diao M; Zhang Z; Jiang M; Chen S; Zhao D; Liu Z; Zhou C
Lung Cancer; 2024 Jan; 187():107439. PubMed ID: 38113653
[TBL] [Abstract] [Full Text] [Related]
16. The interaction of mast cells with membranes from lung cancer cells induces the release of extracellular vesicles with a unique miRNA signature.
Shemesh R; Laufer-Geva S; Gorzalczany Y; Anoze A; Sagi-Eisenberg R; Peled N; Roisman LC
Sci Rep; 2023 Dec; 13(1):21544. PubMed ID: 38057448
[TBL] [Abstract] [Full Text] [Related]
17. Exploring the lncRNA-VEGF axis: Implications for cancer detection and therapy.
Alharthi NS; Al-Zahrani MH; Hazazi A; Alhuthali HM; Gharib AF; Alzahrani S; Altalhi W; Almalki WH; Khan FR
Pathol Res Pract; 2024 Jan; 253():154998. PubMed ID: 38056133
[TBL] [Abstract] [Full Text] [Related]
18. The enrichment of Fanconi anemia/homologous recombination pathway aberrations in ATM/ATR-mutated NSCLC was accompanied by unique molecular features and poor prognosis.
Wei W; Shi F; Xu Y; Jiao Y; Zhang Y; Ou Q; Wu X; Yang L; Lai J
J Transl Med; 2023 Dec; 21(1):874. PubMed ID: 38041093
[TBL] [Abstract] [Full Text] [Related]
19. Association of TOP2A and ADH1B with lipid levels and prognosis in patients with lung adenocarcinoma and squamous cell carcinoma.
Yin D; Zhang Y; Li H; Cheng L
Clin Respir J; 2023 Dec; 17(12):1301-1315. PubMed ID: 37985446
[TBL] [Abstract] [Full Text] [Related]
20. ARID3A and ARID3B exert direct regulatory control over the long non-coding RNAs (lncRNAs) MALAT1 and NORAD within the context of non-small cell lung cancer (NSCLC).
Nasuh S; Balci SO; Bozgeyik I; Ikeda MA; Tekayev M; Saadat KASM
Pathol Res Pract; 2023 Dec; 252():154948. PubMed ID: 37977034
[TBL] [Abstract] [Full Text] [Related]
[Next]
